The Personalized Medicine Biomarkers Market Size is valued at USD 22.9 Bn in 2023 and is predicted to reach USD 59.1 Bn by the year 2031 at an 12.8% CAGR during the forecast period for 2024-2031.
The Personalized Medicine Biomarkers Market is a continuously developing area of healthcare focused on using biomarkers, which are biological markers such as proteins or genetic mutations for individualized treatments. Thus, these biomarkers are useful in all the stages involved in healthcare, starting from preliminary detection of the disease till proper diagnosis, selection of treatment, and monitoring. This approach is aligned with the patient's unique biological profile and, therefore, increases the therapeutic outcomes while minimizing the potential side effects in fields such as oncology, cardiology, and autoimmune diseases.
The key drivers of this market are the increasing incidence of chronic diseases such as cancer, cardiovascular conditions, and diabetes that require more accurate diagnostic and therapeutic solutions. Further, advancements in genomics and proteomics are accelerating the discovery and application of new biomarkers, increasing our understanding of disease mechanisms. These are also revolutionizing drug development, with the identification of appropriate candidates for clinical trials and improved stratification of patients for targeted therapies.
The personalized medicine biomarkers market is segmented by type, application, end user. By type the market is segmented into genetic biomarkers, protein biomarkers, metabolite biomarkers. By application the market is categorized into oncology, neurology, diabetes, autoimmune diseases, cardiology, and others. By end user the market is categorized into hospitals, diagnostic laboratories, research institutions.
The genetic biomarkers segment is a key driver of the Personalized Medicine Biomarkers Market, particularly in oncology, would be the genetic biomarkers segment where their value lies in finding the appropriate specific tumor mutations so that specific targeted therapies might be available for an individual patient for better treatment. The genomics technologies now include advancements in next-generation sequencing that have improved in the discovery of genetic mutations better for predictions related to disease susceptibility and regarding treatment responses. Further regulatory support for companion diagnostics based on genetic biomarkers spurs innovation and drives investment by pharmaceutical companies, fueling the growth of the market.
The Oncology segment is the fastest-growing application area in the Personalized Medicine Biomarkers Market, led by the increasing prevalence of cancer and the growing demand for biomarkers that predict patient responses to targeted therapies and immunotherapies. Cancer cases are expected to rise to 29.5 million by 2040, and the need for accurate diagnostic and therapeutic solutions is growing. Improvements in genomic technologies, including NGS, have transformed cancer diagnostics by allowing the precise determination of genetic mutations that indicate targeted therapy. Moreover, regulatory support from agencies, such as the FDA, which has approved many targeted cancer therapies, continues to further drive investment in biomarker R&D, which further establishes oncology's leadership.
North America is an influential region for the Personalized Medicine Biomarkers Market, mainly due to the presence of big names such as Thermo Fisher Scientific, Illumina, and Guardant Health, leaders in biotechnology that innovate research and development for biomarkers. Advanced healthcare infrastructure in the region along with the latest technologies, such as NGS and liquid biopsies, optimize biomarker identification and personalized treatment. Advances in genomic technologies are also underpinned by the rise in the demand for targeted therapies in the wake of rising chronic disease incidence, especially cancer. Substantial research funding in North America also ensures that collaborations among academic institutions and industry players create a great momentum for personalizing medicines.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 22.9 Bn |
|
Revenue Forecast In 2031 |
USD 59.1 Bn |
|
Growth Rate CAGR |
CAGR of 12.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Application, End User, and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Foundation Medicine, Inc., Genomic Health, Inc, Guardant Health, Inc., Illumina, Inc., Luminex Corporation, Merck KGaA, Myriad Genetics, Inc, QIAGEN N.V, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific Inc., Coriell Life Sciences, Laboratory Corporation of America Holding, NeoGenomics Laboratories, Quest Diagnostics Incorporated |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Personalized Medicine Biomarkers Market by Type -
Personalized Medicine Biomarkers Market by Application -
Personalized Medicine Biomarkers Market by End User -
Personalized Medicine Biomarkers Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
